一种银杏内酯A调控YARS1制备VA-ECMO肺损伤治疗药物的方法
The drug prepared by regulating YARS1 with ginkgolide A solves the problem of lack of precise drug targets for VA-ECMO lung injury, and achieves precise intervention and improved treatment effect for lung injury.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- 中国人民解放军总医院第八医学中心
- Filing Date
- 2026-04-09
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies lack precise molecular targets for lung injury caused by VA-ECMO, making it difficult to effectively alleviate alveolar epithelial cell damage, inflammatory cascade, and oxidative stress.
Using ginkgolide A as a regulator of YARS1 protein, a drug for treating lung injury caused by VA-ECMO was prepared through virtual screening, binding affinity confirmation, and cellular efficacy confirmation. Biophysical confirmation was performed using surface plasmon resonance technology, and its efficacy was verified in vitro and in vivo.
It enables precise intervention for lung injury caused by VA-ECMO, improves lung gas exchange function, repairs alveolar epithelial barrier structure, inhibits inflammation and oxidative stress response, and enhances the therapeutic efficacy and safety under VA-ECMO support.
Smart Images
Figure CN122005544B_ABST